Publication

Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Long-term quality of life analysis results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial

Bottomley, A.
; 
Kicinski, M.
; 
Long, G. V.
; 
Mandala, M.
; 
Atkinson, V. G.
; 
Blank, C. U.
; 
Haydon, A. M.
; 
Dalle, S.
; 
Khattak, A.
; 
Carlino, M. S.
... show 10 more
Citations
Altmetric:
Abstract
Authors
Bottomley, A.
Kicinski, M.
Long, G. V.
Mandala, M.
Atkinson, V. G.
Blank, C. U.
Haydon, A. M.
Dalle, S.
Khattak, A.
Carlino, M. S.
Meshcheryakov, A.
Sandhu, S. K.
Sarda, S. S.
Coens, C.
Suciu, S.
Grebennik, D.
Krepler, C.
Lorigan, Paul C
Robert, C.
Eggermont, A. M. M.
Affiliation
Dept Of Oncology, University College London Hospitals NHS Foundation Trust, UCL Cancer Institute and CRUK Lung Cancer Centre of Excellence, NW1 2PG - London
Description
Date
2022
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Bottomley A, Kicinski M, Long GV, Mandala M, Atkinson VG, Blank CU, et al. Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Long-term quality of life analysis results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial. Annals of Oncology. 2022 Sep;33(7):S1410-S1. PubMed PMID: WOS:000866211602453.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/625984
Embedded videos